Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [21] Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up
    Levy, Manon
    Abeillon, Juliette
    Dalle, Stephane
    Assaad, Souad
    Borson-Chazot, Francoise
    Disse, Emmanuel
    Raverot, Gerald
    Cugnet-Anceau, Christine
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 10
  • [22] Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
    Faiena, Izak
    Cummings, Amy L.
    Crosetti, Anna M.
    Pantuck, Allan J.
    Chamie, Karim
    Drakaki, Alexandra
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 209 - 215
  • [23] Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
    Loo, Kimberly
    Daud, Adil
    IMMUNOTHERAPY, 2016, 8 (07) : 775 - 784
  • [24] Two cases of granuloma annulare under anti-PD1 therapy
    Charollais, R.
    Aubin, F.
    Roche-Kubler, B.
    Puzenat, E.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2018, 145 (02): : 116 - 119
  • [25] Potential of New Therapies like Anti-PD1 in Kidney Cancer
    Gunturi, Anasuya
    McDermott, David F.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2014, 15 (01) : 137 - 146
  • [26] Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
    Fazel, Mina
    Dufresne, Armelle
    Vanacker, Helene
    Waissi, Waisse
    Blay, Jean-Yves
    Brahmi, Mehdi
    CANCERS, 2023, 15 (06)
  • [27] Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
    Tumeh, Paul C.
    Hellmann, Matthew D.
    Hamid, Omid
    Tsai, Katy K.
    Loo, Kimberly L.
    Gubens, Matthew A.
    Rosenblum, Michael
    Harview, Christina L.
    Taube, Janis M.
    Handley, Nathan
    Khurana, Neharika
    Nosrati, Adi
    Krummel, Matthew F.
    Tucker, Andrew
    Sosa, Eduardo V.
    Sanchez, Phillip J.
    Banayan, Nooriel
    Osorio, Juan C.
    Nguyen-Kim, Dan L.
    Chang, Jeremy
    Shintaku, I. Peter
    Boasberg, Peter D.
    Taylor, Emma J.
    Munster, Pamela N.
    Algazi, Alain P.
    Chmielowski, Bartosz
    Dummer, Reinhard
    Grogan, Tristan R.
    Elashoff, David
    Hwang, Jimmy
    Goldinger, Simone M.
    Garon, Edward B.
    Pierce, Robert H.
    Daud, Adil
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (05) : 417 - 424
  • [28] Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
    Shui, Irene M.
    Scherrer, Emilie
    Frederickson, Andrew
    Li, Joyce W.
    Mynzhassarova, Anel
    Druyts, Eric
    Tawbi, Hussein
    MELANOMA RESEARCH, 2022, 32 (06) : 393 - 404
  • [29] Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
    Zhang Jingzhe
    Li Ye
    Yang Shoujun
    Zhang Lening
    Wang Wenjun
    JOURNAL OF BONE ONCOLOGY, 2019, 17
  • [30] Triple combination immunotherapy with GVAX, anti-PD-1 monoclonal antibody, and agonist anti-OX40 monoclonal antibody is highly effective against murine intracranial glioma
    Jahan, Nusrat
    Talat, Hammad
    Alonso, Andrea
    Saha, Dipongkor
    Curry, William T.
    ONCOIMMUNOLOGY, 2019, 8 (05):
12345